SI1641436T1 - Inhalacijska formulacija aztreonam lizinata za zdravljenje in preprečevanje bakterijskih infekcij pljuč - Google Patents

Inhalacijska formulacija aztreonam lizinata za zdravljenje in preprečevanje bakterijskih infekcij pljuč

Info

Publication number
SI1641436T1
SI1641436T1 SI200432105T SI200432105T SI1641436T1 SI 1641436 T1 SI1641436 T1 SI 1641436T1 SI 200432105 T SI200432105 T SI 200432105T SI 200432105 T SI200432105 T SI 200432105T SI 1641436 T1 SI1641436 T1 SI 1641436T1
Authority
SI
Slovenia
Prior art keywords
prevention
treatment
bacterial infections
aztreonam lysinate
pulmonary bacterial
Prior art date
Application number
SI200432105T
Other languages
English (en)
Other versions
SI1641436T2 (sl
Inventor
Alan Bruce Montgomery
Frank-Christophe Lintz
Manfred Keller
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34083679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1641436(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/613,639 external-priority patent/US7214364B2/en
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of SI1641436T1 publication Critical patent/SI1641436T1/sl
Publication of SI1641436T2 publication Critical patent/SI1641436T2/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200432105T 2003-07-03 2004-07-01 Inhalacijska formulacija aztreonam lizinata za zdravljenje in preprečevanje bakterijskih infekcij pljuč SI1641436T2 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/613,639 US7214364B2 (en) 2000-12-27 2003-07-03 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US10/882,985 US7138419B2 (en) 2000-12-27 2004-06-30 Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
PCT/US2004/021517 WO2005007132A1 (en) 2003-07-03 2004-07-01 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
EP04777564.8A EP1641436B2 (en) 2003-07-03 2004-07-01 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections

Publications (2)

Publication Number Publication Date
SI1641436T1 true SI1641436T1 (sl) 2013-12-31
SI1641436T2 SI1641436T2 (sl) 2017-08-31

Family

ID=34083679

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200432105T SI1641436T2 (sl) 2003-07-03 2004-07-01 Inhalacijska formulacija aztreonam lizinata za zdravljenje in preprečevanje bakterijskih infekcij pljuč
SI200432421T SI2158901T1 (sl) 2003-07-03 2004-07-01 Alfa aztreonam lizinat

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200432421T SI2158901T1 (sl) 2003-07-03 2004-07-01 Alfa aztreonam lizinat

Country Status (14)

Country Link
US (1) US7138419B2 (sl)
EP (3) EP2452672A3 (sl)
JP (1) JP2007527398A (sl)
BR (1) BRPI0411949A (sl)
CA (1) CA2530774C (sl)
CY (2) CY1114621T1 (sl)
DK (2) DK2158901T3 (sl)
ES (2) ES2655036T3 (sl)
HK (1) HK1089359A1 (sl)
HU (2) HUE035150T2 (sl)
PL (2) PL1641436T5 (sl)
PT (2) PT1641436E (sl)
SI (2) SI1641436T2 (sl)
WO (1) WO2005007132A1 (sl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
PT2301524E (pt) * 2000-12-27 2013-07-10 Gilead Sciences Inc Aztreonam inalável sem arginina para tratamento e prevenção de infecções bacterianas pulmonares
US7138419B2 (en) † 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
ES2351651B2 (es) * 2003-07-02 2011-09-28 Gilead Sciences Inc. Método para la determinación de impurezas en una sal de lisina de aztreonám amorfa.
CA2733145C (en) * 2003-07-02 2012-06-19 Corus Pharma, Inc. Aztreonam l-lysine and method of determining impurities therein
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US7973029B2 (en) * 2007-10-01 2011-07-05 Gilead Sciences, Inc. Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of-life in lung diseases
CN101912356B (zh) * 2010-08-02 2012-01-11 王明 一种氨曲南/精氨酸药物组合物脂微球注射剂
EP3789031B1 (en) * 2010-09-17 2023-08-02 Technophage, Investigação e Desenvolvimento em Biotecnologia, SA Antibacterial phage, phage peptides and methods of use thereof
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10092552B2 (en) * 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
JP6426696B2 (ja) * 2013-03-14 2018-11-21 センプラ ファーマシューティカルズ，インコーポレイテッド 呼吸器疾患の治療のための方法および製剤
CN104784159A (zh) * 2015-04-15 2015-07-22 苏州惠仁生物科技有限公司 氨曲南粉雾剂的制备方法
CN107805618B (zh) * 2017-12-03 2021-04-06 李峰 一种改造盐碱地耕种性的微生物菌剂及其制备方法
CN110857474B (zh) * 2018-08-24 2023-04-18 武汉远大弘元股份有限公司 L-半胱氨酸盐酸盐一水合物的处理方法
WO2020174365A1 (en) * 2019-02-28 2020-09-03 Exorao Life Science S.R.L. Sterile aztreonam package
JPWO2020261619A1 (sl) * 2019-06-26 2020-12-30

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126A (en) * 1852-07-13 Marcus r
US3984403A (en) † 1972-06-30 1976-10-05 Takeda Chemical Industries, Ltd. Arginine and lysine salts of acid cephalosporins
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
WO1982001873A1 (en) 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
US4673739A (en) 1980-12-05 1987-06-16 Takeda Chemical Industries, Ltd. 4-carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
US4572801A (en) 1981-04-30 1986-02-25 Takeda Chemical Industries, Ltd. 4-Carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
US4946838A (en) 1981-07-13 1990-08-07 E. R. Squibb & Sons, Inc. Crystalline anhydrous aztreonam
US4826973A (en) 1984-07-20 1989-05-02 E. R. Squibb & Sons, Inc. Delta form of aztreonam and preparation thereof
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US4888998A (en) 1986-07-11 1989-12-26 Beckman Instruments, Inc. Sample handling system
CA1339136C (en) 1987-07-01 1997-07-29 Sailesh Amilal Varia Amorphous form of aztreonam
ATE219684T1 (de) 1994-01-14 2002-07-15 Xoma Technology Ltd Anti gram positive bakterielle verfahren und mittel
US5875776A (en) 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US5994340A (en) 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
HU229310B1 (en) 1999-10-29 2013-10-28 Nektar Therapeutics Dry powder compositions having improved dispersivity
PT2301524E (pt) * 2000-12-27 2013-07-10 Gilead Sciences Inc Aztreonam inalável sem arginina para tratamento e prevenção de infecções bacterianas pulmonares
US7138419B2 (en) † 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
WO2003035030A1 (en) * 2001-10-24 2003-05-01 Pari Gmbh Kit for the preparation of a pharmaceutical composition
WO2003075889A1 (en) 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
EP1417958A1 (en) * 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
AU2002356646A1 (en) * 2002-12-11 2004-06-30 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
CA2733145C (en) * 2003-07-02 2012-06-19 Corus Pharma, Inc. Aztreonam l-lysine and method of determining impurities therein

Also Published As

Publication number Publication date
SI2158901T1 (sl) 2018-02-28
HK1089359A1 (en) 2006-12-01
PT1641436E (pt) 2013-11-07
US20050063912A1 (en) 2005-03-24
EP2452672A2 (en) 2012-05-16
EP2158901A3 (en) 2010-03-17
HUS1800012I1 (hu) 2018-03-28
EP1641436A1 (en) 2006-04-05
CY1114621T1 (el) 2016-10-05
US7138419B2 (en) 2006-11-21
WO2005007132A1 (en) 2005-01-27
DK2158901T3 (en) 2018-01-15
EP1641436B1 (en) 2013-09-04
PL2158901T3 (pl) 2018-05-30
EP2158901A2 (en) 2010-03-03
ES2428030T3 (es) 2013-11-05
EP2452672A3 (en) 2013-11-06
PT2158901T (pt) 2018-01-15
PL1641436T5 (pl) 2017-10-31
DK1641436T4 (en) 2017-07-17
DK1641436T3 (da) 2013-09-30
PL1641436T3 (pl) 2014-02-28
CA2530774C (en) 2011-10-18
JP2007527398A (ja) 2007-09-27
SI1641436T2 (sl) 2017-08-31
CA2530774A1 (en) 2005-01-27
CY1119753T1 (el) 2018-06-27
EP1641436B2 (en) 2017-05-10
ES2428030T5 (es) 2017-07-25
ES2655036T3 (es) 2018-02-16
HUE035150T2 (en) 2018-05-02
BRPI0411949A (pt) 2006-08-29
EP2158901B1 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
HK1089359A1 (en) Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
AU2003901008A0 (en) Composition for the treatment and prevention of bacterial infections
ZA200507070B (en) Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
IL180194A0 (en) Topical otic compositions and methods of topical treatment or prevention of otic infections
CY2011012I2 (el) Εισπνευσιμη αζτρεοναμη για τη θεραπεια και την προληψη πνευμονικων βακτηριακων λοιμωξεων
PL1773361T5 (pl) Kompozycje oparte na bakteriach probiotycznych i ich zastosowanie w profilaktyce i/lub leczeniu patologii i/lub zakażeń układu oddechowego oraz poprawie funkcji jelit
EP1594444A3 (en) Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
GB0125222D0 (en) Composition for the treatment of microbial infections
IL171972A0 (en) Compositions and methods for treatment of severe acute respiratory syndrome(sars)
HK1100812A1 (en) Composition for the prophylaxis/treatment of hbv infections and hbv- mediated diseases
IL182785A0 (en) Particles for treatment of pulmonary infection
EP1773374A4 (en) AGAINST FGF2 AS AN ACTIVE AGENT FOR THE TREATMENT AND PREVENTION OF ASTHMA AND CHRONIC OBSTRUCTIVE LUNG DISEASE
NO20054180D0 (no) Behandling av bakterielle sykdommer i andedrettsorganene ved lokal tilforsel av fluorkinoloner
HUE041133T2 (hu) Dalbavancin adagolási módszer bakteriális fertõzések kezelésére
IL189270A0 (en) Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
EP1651255A4 (en) TOPICAL VETERINARY COMPOSITIONS AND METHODS OF TREATING AND PREVENTING INFECTIONS
IL171893A0 (en) Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
IL180459A0 (en) Treatment of bacterial infections
PL374524A1 (en) Composition based on triethyl citrate for the treatment of bacterial infections of the skin
EP1860944A4 (en) NON-SYSTEMIC ANTIBIOTIC FORMULATIONS AND ASSOCIATED METHOD OF USE AND TREATMENT OF SUPERIOR RESPIRATORY TRACT INFECTIONS
IL172768A0 (en) Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
WO2005011602A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
AU2003250522A8 (en) Compositions and methods for treatment and prophylaxis of infections caused by gram positive bacteria
EP1551456A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING RENAL DISEASES
HK1069739A1 (en) Compositions and methods for treatment of microbial infections